NEW YORK, May 7 - A Roche official said today that the Swiss pharma giant will introduce six new diagnostic products over the next 18 months based on the Affymetrix GeneChip platform it licensed in January.
In a widely reported news conference in Switzerland, Heino von Prondzynski, the head of Roche's diagnostics division identified what tests the company plans to introduce into the market.
Initially, the company will roll out the AmpliChip CYP450 microarray for lab use in the US in May. The chip, designed by Roche and manufactured by Affymetrix, will be sold as an analyte-specific reagent.
Then, the company will also launch Affymetrix platform diagnostic tests for human papilloma virus, cystic fibrosis, colorectal cancer, HIV, and leukemia.
Roche officials were not available for comment.